387 related articles for article (PubMed ID: 23707166)
1. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
2. Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
Hirst A; Hyer RN; Janssen RS
Vaccine; 2021 Jul; 39(33):4733-4741. PubMed ID: 34030898
[TBL] [Abstract][Full Text] [Related]
3. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
Rosenthal EM; Hall EW; Rosenberg ES; Harris A; Nelson NP; Schillie S
Vaccine; 2020 Dec; 38(51):8206-8215. PubMed ID: 33160756
[TBL] [Abstract][Full Text] [Related]
4. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update.
Lee GH; Lim SG
Expert Rev Vaccines; 2021 May; 20(5):487-495. PubMed ID: 33783302
[No Abstract] [Full Text] [Related]
5. Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease.
Amjad W; Alukal J; Zhang T; Maheshwari A; Thuluvath PJ
Dig Dis Sci; 2021 Jun; 66(6):2101-2106. PubMed ID: 32617767
[TBL] [Abstract][Full Text] [Related]
6. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
7. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
[TBL] [Abstract][Full Text] [Related]
8. Adult immunization against hepatitis B: Does the number of jabs matter?
Oster G; Bornheimer R; Ottino K; Stevenson C; Lewin C; Janssen R
Vaccine; 2022 Jun; 40(26):3597-3604. PubMed ID: 35570079
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
[TBL] [Abstract][Full Text] [Related]
11. Antibody response to hepatitis B vaccine in end-stage renal disease patients.
Chow KM; Law MC; Leung CB; Szeto CC; Li PK
Nephron Clin Pract; 2006; 103(3):c89-93. PubMed ID: 16534237
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience.
Schnittman SR; Zepf R; Cocohoba J; Sears D
J Acquir Immune Defic Syndr; 2021 Apr; 86(4):445-449. PubMed ID: 33196553
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients.
Tung J; Carlisle E; Smieja M; Kim PT; Lee CH
Am J Kidney Dis; 2010 Oct; 56(4):713-9. PubMed ID: 20630640
[TBL] [Abstract][Full Text] [Related]
14. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
Girndt M; Houser P; Manllo-Karim R; Ervin JE; Charytan C; Chow S; Symonian-Silver M; Lehrner L; Linfert D; Shemin D; Michelsen A; Xie F; Janssen RS
Vaccine; 2023 May; 41(20):3224-3232. PubMed ID: 37085451
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India.
Velu V; Nandakumar S; Shanmugam S; Jadhav SS; Kulkarni PS; Thyagarajan SP
World J Gastroenterol; 2007 Jun; 13(22):3084-9. PubMed ID: 17589924
[TBL] [Abstract][Full Text] [Related]
17. Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV.
Khaimova R; Fischetti B; Cope R; Berkowitz L; Bakshi A
Vaccine; 2021 Oct; 39(44):6529-6534. PubMed ID: 34600748
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States.
Talbird SE; Anderson SA; Nossov M; Beattie N; Rak AT; Diaz-Mitoma F
Vaccine; 2023 May; 41(23):3506-3517. PubMed ID: 37147201
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
